Breaking News Bar
updated: 4/15/2014 9:10 AM

J&J Q1 net up 8 percent on sales jump, lower costs

hello
Success - Article sent! close
  • Johnson & Johnson's first-quarter profit rose 8 percent, because of restrained costs and a big jump in prescription drug sales. The world's biggest maker of health care products easily beat Wall Street expectations and raised its earnings outlook, driving up its shares to a new high for the year.

      Johnson & Johnson's first-quarter profit rose 8 percent, because of restrained costs and a big jump in prescription drug sales. The world's biggest maker of health care products easily beat Wall Street expectations and raised its earnings outlook, driving up its shares to a new high for the year.
    Associated Press

 
Associated Press

Johnson & Johnson's first-quarter profit rose 8 percent, because of restrained costs and a big jump in prescription drug sales.

The world's biggest maker of health care products easily beat Wall Street expectations and raised its earnings outlook, driving up its shares to a new high for the year.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

The maker of Tylenol, medical devices and prescription drugs said Tuesday that net income was $4.73 billion, or $1.64 per share, up from $3.5 billion, or $1.22 per share, a year earlier.

Excluding one-time items, income was $4.43 billion, or $1.54 per share. Analysts surveyed by FactSet expected $1.48.

The company, based in New Brunswick, N.J., said revenue totaled $18.12 billion, up 3.5 percent. Analysts expected $18.04 billion.

Sales of prescription drugs, currently the strongest of J&J's three business segments, jumped 11 percent to $7.5 billion as sales overseas surged 14 percent.

Meanwhile, sales for medical devices and diagnostics were flat at $7.06 billion, and sales of consumer health products fell 3.2 percent to $3.56 billion.

The consumer products business has been hit by dozens of recalls since 2009 for products including pain relievers Tylenol and Motrin. J&J is having to win back customers who switched to cheaper store brands during that period, and some of the products are still not back on store shelves. Also, the company noted that it divested its sanitary protection business.

"Johnson & Johnson delivered strong first-quarter results driven by successful new product launches and the continued growth of key products," CEO Alex Gorsky said in a statement.

In premarket trading, shares rose $2.44, or 2.5 percent, to $99.58, a new 52-week high.

The company raised its profit forecast for 2014 to $5.80 to $5.90 per share. In January, J&J forecast $5.75 to $5.85

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here